Dalvand Sahar, Niksima Seyed Hassan, Meshkani Reza, Ghanei Gheshlagh Reza, Sadegh-Nejadi Sahar, Kooti Wesam, Parizad Naser, Zahednezhad Hossein, Afrisham Reza
Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Dept. of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Public Health. 2017 Apr;46(4):456-467.
Metabolic syndrome (MetS) is the major risk factor for development of type 2 diabetes and cardiovascular diseases in different populations. The aim of this study was to evaluate the prevalence of MetS among Iranian population.
Thirty-four cross-sectional studies were analyzed with a sample of 83227 people. National and international English electronic databases (PubMed, Google scholar, Web of Science, Science Direct, and Scopus) and Persian language databases (SID, Medlib, Iran medex, Magiran, Medlib, and IranDoc) were used to search the articles published on MetS in Iranian population from Jan 2005 to May 2016. The MetS diagnosis was performed according to the ATP-III, NCEP/ATP-III, IDF and WHO criteria.
The overall weighted prevalence of MetS was 31% (95% CI: 28-35). According to ATP III criteria, total and gender-stratified prevalence of MetS in women and men were 29% (95% CI: 22-36), 37% (95% CI: 26-48) and 29% (95% CI: 23-36), respectively. Total prevalence of MetS based on NCEP/ATP III criteria was 29% (95% CI: 24-35) that the prevalence was 24% (95% CI: 18-30) and 35% (95% CI: 25-44) in men and women, respectively. According to the IDF and WHO criteria, total prevalence of MetS were 38% (95% CI: 32-43) and 30% (95% CI: 7-53), respectively.
The findings demonstrate an emerging high prevalence of MetS in total and in particular among Iranian women population. Therefore, to minimize the risk of cardiovascular events in Iranian population, screening and early detection of risk factors for MetS are required.
代谢综合征(MetS)是不同人群发生2型糖尿病和心血管疾病的主要危险因素。本研究的目的是评估伊朗人群中代谢综合征的患病率。
对34项横断面研究进行分析,样本量为83227人。使用国内和国际英文电子数据库(PubMed、谷歌学术、科学引文索引、科学直读和Scopus)以及波斯语数据库(SID、Medlib、Iran medex、Magiran、Medlib和IranDoc)搜索2005年1月至2016年5月在伊朗人群中发表的关于代谢综合征的文章。根据ATP-III、NCEP/ATP-III、国际糖尿病联盟(IDF)和世界卫生组织(WHO)标准进行代谢综合征诊断。
代谢综合征的总体加权患病率为31%(95%置信区间:28-35)。根据ATP III标准,女性和男性中代谢综合征的总患病率及按性别分层的患病率分别为29%(95%置信区间:22-36)、37%(95%置信区间:26-48)和29%(95%置信区间:23-36)。基于NCEP/ATP III标准的代谢综合征总患病率为29%(95%置信区间:24-35),其中男性患病率为24%(95%置信区间:18-30),女性患病率为35%(95%置信区间:25-44)。根据IDF和WHO标准,代谢综合征的总患病率分别为38%(95%置信区间:32-43)和30%(95%置信区间:7-53)。
研究结果表明,代谢综合征在总体人群中,尤其是伊朗女性人群中的患病率正在上升。因此,为了降低伊朗人群心血管事件的风险,需要对代谢综合征的危险因素进行筛查和早期检测。